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Abstract
Here we present our progress in inducing an ectopic brown adipose tissue (BAT) phenotype in skeletal muscle (SKM) as a
potential gene therapy for obesity and its comorbidities. We used ultrasound-targeted microbubble destruction (UTMD), a
novel targeted, non-viral approach to gene therapy, to deliver genes in the BAT differentiation pathway into rodent SKM to
engineer a thermogenic BAT phenotype with ectopic mUCP-1 overexpression. In parallel, we performed a second protocol
using wild-type Ucp-1-null knockout mice to test whether the effects of the gene therapy are UCP-1 dependent. Our main
findings were a robust cellular presence of mUCP-1 immunostaining (IHC), significantly higher expression levels of mUCP-
1 measured by qRT-PCR, and highest temperature elevation measured by infrared thermography in the treated thigh,
achieved in rats after delivering the UTMD-PRDM16/PGC-1a/BMP7/hyPB gene cocktail. Interestingly, the weight loss
obtained in the treated rats with the triple gene delivery, never recovered the levels observed in the controls in spite of food
intake recovery. Our results establish the feasibility of minimally invasive UTMD gene-based therapy administration in
SKM, to induce overexpression of ectopic mUCP-1 after delivery of the thermogenic BAT gene program, and describe
systemic effects of this intervention on food intake, weight loss, and thermogenesis.
Obesity is a common, complex, highly prevalent disorder
currently affecting more than a third of the world’s popu-
lation [1]. Obesity is closely associated with multiple
metabolic disturbances including cardiometabolic diseases
[2]. Diet, exercise, and behavior modifications remain the
current cornerstones of obesity treatment and prevention,
even though they work very poorly for successful long-term
weight loss [3]. Therefore, there is a desperate need of
powerful strategies for the treatment of obesity to achieve
long-term weight loss and maintenance [4]. One appealing
therapeutic approach is to regulate brown adipose tissue
(BAT) function [5]. BAT is the main organ of adaptive
nonshivering thermogenesis (NST) in humans [6]. Brown
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adipocytes have a high mitochondrial content that contains
a specialized protein (mUCP-1) that causes a proton leak
across the inner membrane of the mitochondria, thereby
dissipating energy in the form of metabolic heat [7]. Ectopic
expression of UCP1 in SKM of transgenic (Tg) mice has
been shown to result in a phenotype characterized by
increased energy expenditure, reduced body weight,
reduced fat mass, improved glucose tolerance [8], decreased
muscle energy efficiency, and altered substrate oxidation
[9], as well as increased longevity [10].
Metabolic diseases such as obesity are particularly
attractive candidates for gene therapy [11]. Numerous suc-
cessful studies have used viral vectors for gene therapy
[12] but viral vectors present significant biosafety concerns
[13]. A recent non-viral delivery alternative is ultrasound-
targeted microbubble destruction (UTMD) [14]. This site-
specific approach infuses a transgene precoupled to
gas-filled lipid microbubbles that are burst within the
microvasculature of the target tissue via an ultrasound (US)
signal, resulting in DNA release and transfection of neigh-
boring cells within the tissue [15]. Our group is actively
engaged in developing optimal tissue-specific UTMD
techniques for gene transfection [16], which we have
applied to cardiometabolic disorders in rodents and non-
human primates. This work has included UTMD delivery of
genes in the differentiation pathway of pancreatic β-cell
function in both rats [17] and baboons [18, 19] to reverse
streptozotocin-induced β-cell destruction and diabetes.
Previous work has also documented that UTMD delivery of
adiponectin to SKM enhanced serum adiponectin levels and
improved hepatic insulin resistance, showing that UTMD
efficiently delivered the adiponectin gene to skeletal muscle
(SKM) improving insulin sensitivity and glucose home-
ostasis [20].
To address BAT-mediated approaches to obesity, we
recently conducted a small proof-of-concept study to show
that by administering tissue-specific UTMD gene therapy,
we could obtain overexpression of mUCP-1 in the SKM of
obese Zucker ZDF fa/fa rats. BAT and SKM cells share
common precursors, and BAT is developmentally closer to
SKM than to white adipose tissue (WAT) [21]. We therefore
treated rat SKM via UTMD with plasmids driving BMP7/
PRDM16/ PPARGC1A genes – part of the gene cascade that
induces BAT differentiation and expression of UCP-1.
Controls received plasmids driving the DsRed reporter gene.
Despite the small number of animals available for our pilot,
we found that the administration of the gene cocktail to
SKM in this rat model of genetic obesity engineered a BAT
phenotype with mUCP-1 overexpression [22].
For this study, our aims were (a) to replicate and further
characterize our previous findings [22] in a larger cohort of
wild-type rodents through UTMD delivery of a cocktail of
thermogenic BAT genes (BMP7, PRDM16 and PGC-1a) to
SKM to induce ectopic mUCP-1 overexpression and ther-
mogenesis; (b) to document if the results obtained with the
cocktail of thermogenic BAT genes may offer some
advantage when compared with delivery of PRDM16 alone;
and (c) to test our gene therapy protocol in UCP-1 null
knockout mice to determine if the effects of the intervention
are UCP-1 dependent, as expected.
Results
Study design
Protocol-1: A total of 24 wild-type Sprague–Dawley rats
received: (1) UTMD with pXL-BSII-CI-DsRed/hyPB
plasmids (controls, n= 6); (2) UTMD with pCMV-
PRDM16 plasmid (n= 6); (3) UTMD with pXL-BSII-CI-
PRDM16/hyPB plasmids, and (4) UTMD with PRDM16/
PGC-1α/BMP7/hyPB plasmids (n= 6). Protocol-2: A total
of 30 C5BL/6 mice received: (1) WT mice: UTMD-pXL-
BSII-DsRed/hyPB (n= 10); (2) WT mice: UTMD-pXL-
BSII-CI-PRDM16/hyPB (n= 10), and (3) mUCP-1 -/- ko
mice: UTMD-pXL-BSII-CI-PRDM16/hyPB (n= 10).
Food intake changes
We fed rats with access to 20 g/day and mice with 3.5 g/day
of a rodent high-fat diet for 1 month before performing
UTMD gene delivery and then continued feeding with the
same diet 1 month after UTMD procedures. The rats were
eating ~ 94 Kcal/day and the mice ~ 16.5 Kcal/day on the
high-fat diet (4.73 Kcal/g) before the gene therapy. Figure 1a
shows that food intake in rats (Protocol-1) sharply decreased
in all animals within the first 3 days to 2–4 g (UTMD-
PRDM16/hyPB or UTMD-PRDM16/PGC-1a/BMP7/hyPB),
to 6–12 g (UTMD-pCMV-PRDM16), and to 16–18 g in the
UTMD-DsRed/hyPB controls. Rats from all groups gradu-
ally increased their daily food intake between days 4 and 10,
recovering the intake levels prior to UTMD gene therapy by
day 20. Figure 1b shows that Protocol-2 mouse food intake
also sharply decreased to 1 g after WT or UCP-1-/- ko mice
received UTMD-PRDM16/hyPB. Both groups recovered
their daily food intake between days 3 and 10, with a sharper
increase in the UCP-1-/- ko mice. The group receiving
UTMD-PRDM16/hyPB steadily kept their food intake after
day 4 in 2.5 g until day 30. WT mice receiving UTMD-
DsRed/hyPB slightly decreased their food intake to 2.5 g
and immediate recovered pre-UTMD administration levels.
Weight and fat loss
In the rat model (Fig. 1c), body weights were not sig-
nificantly different at baseline (~550 g, day 0). There was an
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interesting variation in their weight by day 30 after UTMD
gene delivery, reaching 614 ± 9, 586 ± 10, 535 ± 8, and 528
± 10 g in the UTMD-DsRed/hyPB group, UTMD-pCMV-
PRDM16 group (p < 0.001 vs DsRed control group, n= 6),
UTMD-PRDM16/hyPB group (p < 0.001 vs DsRed control
group, n= 6), and UTMD-PRDM16/PGC-1a/BMP7/hyPB
group (p < 0.001 vs DsRed control group, n= 6), respec-
tively. Figure 2a shows noticeable body weight loss in the
UTMD-PRDM16/hyPB mice group and UTMD-PRDM16/
PGC-1a/BMP7/hyPB group when compared with the
UTMD-DsRed/hyPB or UTMD-pCMV-PRDM16 groups.
Subcutaneous abdominal fat thickness was measured with
US image in the rat model and the results showed that it was
reduced in the PRDM16 gene administration or the gene
cocktail delivery groups when compared with DsRed or
pCMV-PRDM16 groups (p < 0.05) (Fig. 2b). In the mice
model, their body weights were practically similar at
baseline (~22 g, day 0). One month post UTMD treatment,
their weights were 26.7 ± 1.3, 21.2 ± 1.2, and 25.9 ± 1.4 g:
UTMD-DsRed/hyPB group, WT mice: UTMD-PRDM16/
hyPB group (p < 0.001 vs DsRed control group, n= 10),
and UCP-1-/- ko mice: UTMD-PRDM16/hyPB group (p >
0.05 vs DsRed control group, n= 10) (Fig. 1d).
Thermogenesis measured through infrared
technology
We measured temperature changes [23] in both rodent
models, using an infrared digital thermographic camera [24]
and found that their temperature increased in the targeted
local left thigh area when compared with the right thigh
control at 14 days or 28 days post UTMD gene delivery (p
< 0.05 vs control thighs or DsRed group) (Fig. 2c, d).
Overexpression of mUCP-1 in the rat model
We expected the gene cocktail or PRDM16 alone to induce
mUCP-1 overexpression in the targeted SKM area because
mUCP-1 is their direct downstream gene product. Immu-
nohistochemistry (IHC) from Fig. 3 shows that a remark-
able mUCP-1 signal was detected in rat SKM cells 1 month
after UTMD-pXL-BASII-CI-PRDM16/BMP7/PGC-1α
gene cocktail was delivered to the site-specific left thighs
(Fig. 3g), also detected in lesser intensity in the UTMD-
pXL-BASII-CI-PRDM16/hyPB (Fig. 3e), but it was not
seen in the right thigh controls (Fig. 3f-h) nor in the controls
treated with the UTMD-DsRed reporter gene (Fig. 3a, b).
Fig. 1 a A graphic for daily food intake (grams) in the rat model.
Values are presented as mean ± SEM, n= 6 per group; *p < 0.05, **p
< 0.001 vs DsRed control groups. b A graphic for daily food intake
(grams) in the mice model. Values are presented as mean ± SEM, n=
10 per group; *p < 0.05, **p < 0.001 vs control groups. c A graphic for
rat body weights (grams). Values are presented as mean ± SEM, n= 6
per group; *p < 0.05, **p < 0.001 vs DsRed control groups. d A gra-
phic for mice body weights (grams). Values are presented as mean ±
SEM. n= 10 per group; *p < 0.05, **p < 0.001 vs control groups
Ectopic BAT mUCP-1 overexpression in SKM by delivering a BMP7/PRDM16/PGC-1a gene cocktail or single. . .
mUCP-1 signal was significantly decreased in the regular
CMV promoter driving the PRDM16 plasmid group
(Fig. 3c). The results of the mUCP-1 quantitative reverse
transcriptase-PCR (qRT-PCR) gene expression (Fig. 3i)
shows that mUCP-1 complementary DNA (cDNA) levels in
the treated left thigh after UTMD-pXL-BASII-CI-PRDM16/
BMP7/PGC-1α gene cocktail were 36 ± 9-fold greater than
UTMD-pXL-BASII-CI-PRDM16/hyPB alone (18 ± 3-fold;
p < 0.001).
PRMD16 signal in rat SKM after UTMD gene delivery
We measured PRDM16 IHC and expression with both
CMV promoter-driven plasmids and hyPB transposon
plasmids in our UTMD gene delivery system. IHC from
Fig. 3 also shows that a significant rat PRDM16 signal was
detected in SKM cells 1 month after UTMD-pXL-BASII-
CI- PRDM16/hyPB or PRDM16/BMP7/PGC-1α gene
cocktail delivered to the left thighs (Fig. 3n-p) but was
not detected in the right thigh controls (Fig. 3o-q), nor in
the controls treated with UTMD-DsRed reporter gene
(Fig. 3j, k). Moreover, PRDM16 signal was very weak in
the regular CMV promoter driving the PRDM16 plasmid
group (Fig. 3l). PRMD16 qRT-PCR gene expression
showed a level of 76 ± 4-fold and 82 ± 8-fold after UTMD-
pXL-BASII-CI-PRDM16/BMP7/PGC-1α gene cocktail and
UTMD-pXL-BASII-CI-PRDM16/hyPB, respectively (p <
0.001) (Fig. 3r).
mUCP-1 and PRMD16 signal in mice SKM after
UTMD gene delivery
In the mouse model, we observed robust expression of
mUCP-1 in wild-type, but not in mUCP-1-/- ko mice after
UTMD-pXL-CI-PRDM16/hyPB. IHC from Fig. 4 shows
that a mUCP-1 signal only existed in the treated left thigh
from WT mice (Fig. 4c) but it was not seen in mUCP-1-/-
ko mice and right thigh controls (Fig. 4d, e), nor in the
controls treated with UTMD-DsRed reporter gene (Fig. 4a).
qRT-PCR results show that mUCP-1 cDNA levels in the
treated thigh of the WT mice group after UTMD-pXL-
BASII-CI- PRDM16/hyPB was, as expected, 45 ± 4-fold
greater than in the thigh of the mUCP-1-/- knockout mice
group (p < 0.001). It also showed no difference between
treated and control thigh in the mUCP-1-/- knockout mice
(Fig. 4g). We also achieved decent overexpression of
PRDM16 in either the wild-type or UCP-1-/- knockout
mice. IHC from Fig. 4 shows that PRDM16 signal only
existed in the treated left thigh in WT mice or mUCP-1-/-
ko mice (Fig. 4j-l) but are not seen in right thigh controls
(Fig. 4j-l), nor in the controls treated with UTMD-DsRed
reporter gene (Fig. 4k-m). qRT-PCR results show that
Fig. 2 a A graphic for rat body weight changes (grams). Values are
presented as mean ± SEM, n= 6 per group; **p < 0.001 vs DsRed
control groups. b A graphic for the thickness of the abdominal sub-
cutaneous fat layer, Values are presented as mean ± SEM, n= 6 per
group; *p < 0.05 vs control groups. c A graphic for temperature (F) on
rat thighs. Values are presented as mean ± SEM, n= 6 per group; *p <
0.05 vs control groups. d A graphic for temperature (F) on mice thighs.
Values are presented as mean ± SEM, n= 10 per group; *p < 0.05 vs
control groups
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PRDM16 cDNA levels in treated thigh of WT mice or
mUCP-1-/- ko mice group after UTMD-pXL-BASII-CI-
PRDM16/hyPB were 86 ± 5 and 81 ± 7-folds greater,
respectively, than in thigh controls treated with UTMD-
DsRed/hyPB (p < 0.001; Fig. 4n).
Perilipin A signal in SKM after UTMD gene delivery
We further investigated if expression of perilipin A, an
adipocyte-specific marker [25], was induced in the targeted
SKM area. Figure 5 shows that a remarkable expression of
perilipin A was only seen in WT mice but not in UCP-1-/-
knockout mice or DsRed mice after UTMD-pXL-CI-
PRDM16/hyPB. A perilipin A signal was only identified in
the treated left thigh from WT mice (Fig. 5c) but it was not
seen in mUCP-1-/- knockout mice and the right thigh
controls (Fig. 5d, e), nor in the controls treated with UTMD-
DsRed reporter gene (Figs. 5a, b). qRT-PCR results
show that Perilipin A cDNA levels in the treated thigh of
the WT mice group after UTMD-pXL-BASII-CI- PRDM16/
hyPB was 66 ± 5-fold greater, than in right thigh controls
(p < 0.001). There was no difference between the thigh
treated with UTMD-DsRed/hyPB and thigh controls from
the mUCP-1-/- knockout mice group (Fig. 5m). Western
blotting shows that the perilipin A signal in the treated left
thigh of WT mice was significantly stronger than in UCP-
1-/- ko mice after UTMD-pXL-BASII-CI- PRDM16/hyPB
gene delivery (Fig. 5r). Western blotting also shows that a
significant mUCP-1 signal existed in treated left thigh of
WT mice, but not in mUCP-1-/- ko mice after UTMD-
pXL-BASII-CI- PRDM16/hyPB gene delivery (Fig. 5r).
Perilipin is an important regulator of lipid storage [26], so
we further co-stained it with the neutral lipid dye oil red O
[25]. We observed the stained lipid droplets in SKM.
Figure 5i clearly shows that neutral lipid droplets and lipid
droplet-associated protein (perilipin A) co-stained in the
targeted SKM area but they are not seen in mUCP-1-/- ko
mice or right thigh controls (Fig. 5j, k), nor in the controls
treated with UTMD-DsRed reporter gene (Fig. 5g, h).
Figure 5o through 5r are magnified images (white square
from panel I) clearly showing tiny lipid droplets in SKM
cells.
Fig. 3 Overexpression of mUCP-1 gene in adult rat skeletal muscle
after UTMD treatment. a UTMD-DsRed/hyPB gene plasmids on left
thigh. b Right thigh for control. c UTMD-pCMV-PRDM16 gene
plasmids on left thigh. d Right thigh for control. e UTMD-PRDM16/
hyPB gene plasmids on left thigh. f Right thigh for control. g UTMD-
PRDM16/PGC-1a/BMP7/hyPB plasmids on left thigh. h Right thigh
for control. Scale bar is 50 µm. i A qRT-PCR for mUCP-1 cDNA
level. Values are presented as mean ± SEM. n= 6 per group; **p <
0.001 vs control thighs or DsRed group. Overexpression of PRDM16
gene in adult rat skeletal muscle after UTMD gene delivery. j UTMD-
DsRed/hyPB gene plasmids on treated left thigh showing expression
of the reporter gene (bright red signal); k same as panel j but on right
thigh for control. l UTMD-pCMV-PRDM16 gene plasmids on left
thigh. m Right thigh for control. n UTMD-PRDM16/hyPB gene
plasmids on left thigh. o Right thigh for control. p UTMD-PRDM16/
PGC-1a/BMP7/hyPB plasmids on left thigh. q Right thigh for control.
Scale bar is 50 µm. r A qRT-PCR for PRDM16 cDNA level. Values
are presented as mean ± SEM, n= 6 per group; **p < 0.001 vs control
thigh or DsRed group (color figure online)
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Discussion
In this study, we engineered overexpression of ectopic
mUCP-1, which functions to dissipate energy as heat, in
SKM of mice and rats through delivery of thermogenic
BAT genes using non-viral, site-specific UTMD gene
therapy, and replicate and expand upon previous findings
[22]. In particular, we have generalized our previous find-
ings in the Zucker fa/fa diabetic fatty (ZDF) [22] to different
rodent strains: wild-type Sprague–Dawley rats (N= 24),
wild-type C57BL/6 mice (N= 20) and heterozygous for
mUCP-1tm1Kz mice (N= 10).
SKM as target for BAT induction
“Brite”, “beige”, “inducible brown”, or “recruitable brown”
adipocytes [27] exist among white adipocytes and upon
stimulation by chronic cold exposure (or other mechanisms
that mimic beta-adrenergic stimulation) they become mul-
tilocular and begin expressing UCP1 [28]. WAT browning
is stimulated by a complex hormonal interplay and
numerous environmental factors such as prolonged cold
exposure, β-adrenergic agonist treatment and exercise, and
at the molecular level, it is regulated by multiple factors and
signaling pathways. A key factor is Peroxisome proliferator-
Fig. 4 Overexpression of mUCP-1 and PRMD16 gene in adult mice
skeletal muscle after UTMD gene delivery. UCP1: a Wild-type mice:
UTMD-DsRed/hyPB gene plasmids on left thigh. b Right thigh for
control. c WT mice: UTMD-PRDM16/hyPB gene plasmids on left
thigh. d Right thigh for control. e mUCP-1 -/- ko mice: UTMD-
PRDM16/hyPB plasmids on left thigh. f Right thigh for control. Scale
bar is 50 µm. PRMD16: h Wild-type mice: UTMD-DsRed/hyPB gene
plasmids on left thigh. i Right thigh for control. j WT mice: UTMD-
PRDM16/hyPB gene plasmids on left thigh. k Right thigh for control.
l mUCP-1-/- ko mice: UTMD-PRDM16/hyPB plasmids on left thigh;
m Right thigh for control. Scale bar is 50 µm. g A graphic for qRT-
PCR for mUCP-1 cDNA level. Values are presented as mean ± SEM,
n= 10 per group; **p < 0.001 vs control groups. n A graphic for qRT-
PCR for PRDM16 cDNA level. Values are presented as mean ± SEM.
n= 10 per group; **p < 0.001 vs control groups
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activated receptor-gamma coactivator (PGC-1α) acting as
master regulator of mitochondrial biogenesis and oxidative
metabolism in adipocytes and inducing the expression of
UCP1 [29]. Therefore, browning of WAT has attracted
attention as a potentially important, efficient strategy to treat
obesity and its related metabolic disorders. However, WAT
has very few mitochondria and stores triglycerides in a
single lipid droplet, whereas the BAT has an enormous
number of mitochondria in depots that are highly innervated
and vascularized [30]. Brown fat has a tremendous capacity
to oxidize fatty acids and generate heat, due to the presence
of its unique gene coding for the uncoupling protein mUCP-
1 [31]. In reality, BAT have striking similarities to SKM
than WAT [21]. Indeed, the developmental origins of BAT
and WAT are overall distinct, with brown adipocytes being
derived from muscle precursors. Myf5-negative white adi-
pocytes are derived from blood-vessel-associated pericyte-
like cells [32]. Unlike WAT, a common lineage for SKM
and brown fat cells has been proposed arising from the
dermomyotome. Both brown adipocytes and myocytes
express myogenic factors such as Myf5 positive [33], and a
strong correlation between BAT and SKM had already been
recognized in gene expression profiling experiments indi-
cating that they share similar mRNAs [34].
From an evolutionary perspective, BAT obtained the
outstanding ability to develop thermogenic tissue of myo-
genic origin, to produce metabolic heat, to rapidly mobilize
lipid droplets, and, very similar to SKM, to possess large
amounts of mitochondria [35]. SKM and BAT seems to be
complementary in their function. It is suggested that these
organs maintain a functional crosstalk [36] and commu-
nicate with each other through myokines and adipokines
during high metabolic demand including thermogenesis
[37]. SKM is better vascularized compared with WAT. This
was another important factor in choosing this tissue as our
main target to deliver thermogenic BAT genes with the
UTMD technique because high vascularity is a key deter-
minant of BAT vs WAT destiny [38]. Therefore, some
investigators currently consider BAT as a kind of specia-
lized muscle [22]. One interesting hypothesis postulates that
that SKM mitochondrial uncoupling drives endocrine
crosstalk through the induction of myokine FGF21 released
Fig. 5 Overexpression of brown adipose marker, perilipin A in adult
mice skeletal muscle after UTMD gene delivery. a Wild-type mice:
UTMD-DsRed/hyPB gene plasmids on left thigh. b Right thigh for
control. c WT mice: UTMD-PRDM16/hyPB gene plasmids on left
thigh. d Right thigh for control. e mUCP-1 -/- ko mice: UTMD-
PRDM16/hyPB plasmids on left thigh. f Right thigh for control. Scale
bar is 50 µm. Colocalization of adipose marker, perilipin A and the
neutral lipid dye oil red O in adult mice skeletal muscle after UTMD
gene delivery. g Wild-type mice: UTMD-DsRed/hyPB gene plasmids
on left thigh. h Right thigh for control. i WT mice: UTMD-PRDM16/
hyPB gene plasmids on left thigh. j Right thigh for control.
k mUCP-1 -/- ko mice: UTMD-PRDM16/hyPB plasmids on left thigh.
l Right thigh for control. Scale bar is 20 µm. o-r Magnified white
square from panel I. m A graphic for qRT-PCR for perilipin A cDNA
level. Values are presented as mean ± SEM, n= 10 per group; **p <
0.001 vs control groups. n Western blots detecting PRDM16, mUCP-
1, and perilipin A proteins in skeletal muscle
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from SKM with endocrine effects leading to increased
browning of WAT and can explain the healthy metabolic
phenotype of UCP1-Tg mice [39]. PGC-1a is required for
the expression of UCP1 in WAT and for the browning
effect of FGF21 [40].
In vitro immunostaining (IHC) for cell markers is an
indirect method of gene amplification allowing identifica-
tion of the histological origin of the cell indicating its
function in vivo when the correct antibody is used [41].
Overall, the IHC data from the treated left thigh of the rat
model (Fig. 3) show qualitative positive results for the
presence of mUCP-1 and PRMD16, compared with the
negative staining from SKM of the right thigh. Particularly,
Fig. 3g, p strikingly show robust cellular presence of
mUCP-1 and PRMD16 immunoexpression in the treated
thigh after delivering the UTMD-PRDM16/PGC-1a/BMP7/
hyPB gene cocktail. This IHC pattern for protein expression
was followed by the mice group showing the presence of
mUCP-1 and PRMD16 after the WT group received the
PRDM16/hyPB gene therapy (Fig. 4c), also showing
negative staining for UTMD-DsRed/hyPB or mUCP-1 in
the mUCP-1-/- ko mice (Fig. 4a, e).
These IHC data were reinforced and corroborated by
quantitative RT-PCR analysis measuring rat PRDM16 and
mUCP-1 cDNA levels. RT-PCR-based analysis of DNA
offer a precise quantitative analysis of gene amplification
[42], adding sensitivity and specifity to our conventional
IHC [43]. Following the results of the rat IHC data from
Fig. 3, rat mUCP-1 and PRDM16 cDNA levels were sig-
nificantly higher (p < 0.001) in the treated thigh after gene
expression with piggybac transposon plasmids in our
UTMD gene delivery system when compared with the gene
expression with regular CMV or the controls treated with
UTMD-DsRed reporter gene (Fig. 3i, r). Quantification of
the mUCP-1 (Fig. 4g) showed high mUCP-1 levels in the
WT but not in the mUCP-1-/- ko mice treated with the
PRDM16/hyPB gene therapy. These findings were con-
firmed with western blotting by measuring PRDM16 and
mUCP-1 protein content in the mice biopsy samples after
UTMD gene therapy corroborating that the changes in
mRNA expression levels resulted in changes in protein
content (Fig. 5n). As it is shown in Fig. 5, we corroborated
these findings with IHC and molecular measurements (RT-
PCR and western blotting) of perilipin A, a specific marker
of adipocytes including brown adipocytes [25], in the SKM
of our treated rodents. We detected significant over-
expression of perilipin A in SKM [44].
Effects on food intake
The food intake results (Fig. 1a, b) showed that the 30-day
food intake pattern after gene therapy describes a tick mark-
shaped (✓) diagram where the shape sharply falls within the
first 3 days in our treated rats and WT or mUCP-1-/- ko
mice receiving UTMD gene therapy with either the
PRDM16/hyPB or the PRDM16/PGC-1a/BMP7/hyPB gene
cocktail. Both rat and mice treated groups gradually
increased their daily food intake, practically recovering the
intake levels previous to gene therapy by day 30. These data
show that the gene therapy to rats with either the PRDM16/
hyPB or the PRDM16/PGC-1a/BMP7/hyPB gene cocktail
and WT mice treated with UTMD-PRDM16/hyPB gene
delivery consistently reduce daily food intake for short
term, also describing the association between the amounts
of food consumption and UTMD-based gene administration
in SKM. Figures 1c, d show that the rats and mice started
the treatment with UTMD gene therapy weighing ~550 g
and ~22 g, respectively. The rat group intervened with the
PRDM16/hyPB or the PRDM16/PGC-1a/BMP7/hyPB gene
cocktail ended up weighing ~500 g compared with the rats
receiving pCMV-PRDM16 or UTMD-DsRed/hyPB, which
ended up with a final weigh similar or higher to the one
previous to the UTMD treatment (~600 g). The rat weight
change and subcutaneous (SQ) fat loss (fat thickness eval-
uated with US image) from the hyPB-treated rats also
resulted in a far greater percentage from fat mass compared
with pCMV rats or hyPB/DsRed controls (Fig. 2a, b). The
WT or mUCP-1-/- ko mice receiving the PRDM16/hyPB or
UTMD-DsRed/hyPB increased their body weight at the end
of 30 days (~27 g), also showing that the WT group
receiving the PRDM16/hyPB maintained a quasi-flat line
without any significant increase or decrease weight for
30 days.
Thermogenesis
We used a new technique to measure BAT thermogenesis
using infrared imaging following our UTMD gene therapy
[23]. Figure 2c, d clearly show that in both rat and mice
models there were an increase in body surface temperature
observed using this method in the treated animals. The
highest temperature elevation seems to have been achieved
in rats with the administration of the UTMD-PRDM16/
PGC-1a/BMP7/hyPB gene cocktail. These results may
indicate that the significant increased temperature was due
to mUCP-1-mediated thermogenesis. These findings repre-
sent the first standardized use of infrared imaging to spe-
cifically detect mUCP-1 activity after UTMD gene therapy,
indicating that infrared thermography specifically detects
mUCP-1-mediated thermogenesis in vivo and metabolic
heat production in SKM [24].
Gene cocktail vs. single-gene therapy
We examined whether the administration of a cocktail of
three thermogenic BAT genes (PRDM16, BMP7, PGC1A)
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or single PRMD16 into SKM could show phenotypic dif-
ferences and produce enhanced effects on measurements for
body weight, body weight changes, daily food intake, sur-
face thigh temperature measured with infrared technology,
and abdominal subcutaneous fat thickness between triple
compared with single-gene delivery. Our results may have
offered a pattern indicating a fairly appropriate response to
this query at this time. What we obtained was a much more
positive and intense mUCP-1 and PRMD16 overexpression
detected through IHC, and significantly higher expression
levels of these genes measured by qRT-PCR, accurately
localized in SKM surrounding the site of the thigh exposed
to US implementation in the treated rats and mice as shown
in Figs. 3 and 4 after UTMD administration with either
triple delivery or single-gene therapy. These molecular
observations nicely correlated with measurements by ther-
mal infrared imaging showing a significant increase in
surface temperature in the same SKM site (Fig. 2c, d).
Our data did not categorically answer if the administra-
tion of the gene cocktail has an advantage over the single-
gene effects. The rat and mice body weight changes,
abdominal SQ fat thickness and weight loss showed similar
patterns in either the delivery with UTMD-PRDM16/PGC-
1a/BMP7/hyPB gene cocktail or single-gene therapy with
the UTMD-PRDM16/hyPB. However, it seems that there
are key data to suggest that the use of UTMD-based triple
gene delivery is slightly more effective than single
PRMD16 gene delivery. These data include the apparently
higher expression of UCP-1 protein (Fig. 3g vs. 3e) in the
triple than in the single, strongly supported by the qRT-PCR
measurements (Fig. 3i), and the temperature elevation
observed in rats with the administration of the UTMD-
PRDM16/PGC-1a/BMP7/hyPB gene cocktail (Fig. 2c). A
pertinent clarification is the rationale to utilize UTMD-
PRDM16/PGC-1a/BMP7/hyPB gene cocktail or single-
gene therapy with the UTMD-PRDM16/hyPB. The justifi-
cation for choosing the triple cDNA construct was to mimic
in SKM the complete set of genes key for the control and
transcriptional regulation of classic brown fat cell differ-
entiation and activation. BMP7 acts in an autocrine manner
to induce brown committed (UCP1-neg) preadipocytes [45],
also inducing the expression of PRDM16 [46], which pro-
motes the differentiation of mature brown adipocytes and
suppresses both the WAT and the myogenic differentiation
pathway, leading to the expression of PGC1α [47], which
highly activates the expression of the final cellular product,
the brown adipocyte-specific gene mUCP-1, the hallmark of
BAT, leading to metabolic heat production [48]. Given that
PRDM16 functions as the BAT key regulator [49], we
decided to compare the effects of this single gene vs the
triple construct.
It is critically important to obtain higher UCP1 over-
expression levels. It would contribute to produce powerful
clinically translated thermogenic effects and metabolic heat
production on food intake and energy expenditure. This is
what we achieved with the triple gene delivery: an energy
gap [50] that accurately explains why the rats gradually
recovered their food intake patterns by day 30, when
compared with the patterns they showed before gene ther-
apy administration and to the food intake of their controls.
The weight loss in the treated rats never recovered the levels
observed in the controls in spite of food intake recovery
(Fig. 1) [51]. Under the concept of an energy gap [52] of
~50 g weight loss in 30 days, the treated rats did not regain
their initial weight practically without a significant change
in energy intake as Kcal/day. We did not observe an
overwhelming energy gap in the mice in this study
experiencing single PRMD gene delivery as we did in the
rat model. Energy expenditure represented by thermogen-
esis is likely to explain the weight loss maintained in these
rats regardless of food intake gradual recuperation, clearly
indicating BAT mUCP1 over activity and metabolic heat
production secondary to UTMD gene therapy in SKM [53].
This finding follows to a certain extent similar explanations
for the efficacy of long-term weight loss achieved by bar-
iatric surgery and its effectiveness to stimulate daily energy
expenditure as the energy gap [54] for long-term main-
tenance with apparent scanty changes in daily energy intake
[55]. The precise interpretation of the higher gene expres-
sion of UCP-1 protein shown in Fig. 3g, i, the temperature
elevation in Fig. 2c, and the energy gap concept, may lead
to support that short-term UTMD-based triple gene delivery
is slightly more effective than single PRMD16 gene deliv-
ery. A question remains to be seen is if this UCP1 higher
activity obtained with the triple gene delivery could have
some significant advantage in long-term results. Obese
patients have a tendency to regain the weight that they lose.
If, in response to weight loss, one can steadily stimulate the
classical BAT machinery and browning of WAT, it would
help weight loss maintenance [56].
Limitations
Two study design limitations of our study were: (1) we did
not measure classical BAT markers such as PGC1a,
CIDEA, PRDM16, ZIC1, LHX8, UCP1, BMP7 [57]; and
(2) we did not include in vivo energy expenditure data, or
plate-based respirometry of SKM mitochondria, to show
that ectopic expression of UCP1 in SKM is functional and
contributes to energy metabolism. However, combining
UTMD-based gene therapy and BAT are novel research
fields still with a lot of gaps in the knowledge base that need
to be filled. Our next step would be to build a stronger
overall evidence base.
Our early research finding raise several important ques-
tions: (a) given the results obtained with perilipin A, are we
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ectopically differentiating myogenic precursors to fully
differentiated brown fat adipocytes? (b) We have not yet
analyzed whether these UCP-1-expressing cells express
myocyte specific proteins such as MyoD, MyoGenin,
MF20, and Dystrophin analyzed by IHC and pRT-PCR
[58]. Therefore, do we characterize myocytes expressing
brown fat markers or brown fat adipocytes in between
myocytes? (c) Is the age of the animals relevant in the
context of the pool of stem cells differentiating and the rate
at which they commit to full differentiation as they would
change with age? (d) Would this research strategy be suc-
cessful in old animals? (e) Would the early hypophagia
induced by PRDM16 gene delivery in the mUCP-1-/- ko
mice suggest that this effect is not determined by a brown
fat phenotype? (f) How fast can UCP1 be induced after gene
delivery? These queries would be addressed within the
future directions of the research strategy. Also, assuming
that the work of this project proceeds as planned, our next
steps will be to determine the time course of production of
UCP-1 following organ-specific gene therapy delivered via
UTMD to SKM in a non-human primate model [19].
In summary, our study reaffirms the feasibility of UTMD
gene-based therapy administration in SKM, by document-
ing the overexpression of ectopic mUCP-1 by IHC, RT-
PCR, and western blotting after delivery of the thermogenic
BAT gene program. These findings suggest that the
increased thermogenesis and weight loss were elicited by a
single administration of UTMD-based transgenes, obtaining
localized mUCP-1 overexpression in SKM. Our results
ratify SKM as an important therapeutic target for endocrine
regulation of whole body metabolism.
Methods
Experimental rodents
Animal studies were performed according to NIH recom-
mendations and approved by our institutional animal
research committee. All phenotypes and molecular techni-
ques (IHC, RNA isolation and quantitative RT-PCR ana-
lysis, and western blotting) were measured in wild-type
Sprague–Dawley male rats, wild-type (Ucp-1+/+), and Ucp-
1-null (Ucp-1-/-) mice. Protocol-1: Wild-type
Sprague–Dawley male rats at average body weight of 250
g were purchased from Harlan Laboratories (Indianapolis,
IN, USA), housed in a temperature-controlled environment
maintained at 30 ˚C under a 12:12-h light–dark cycle.
Protocol-2: Wild-type C57BL/6 mice and heterozygous for
mUCP-1tm1Kz mice were purchased from the Jackson
Laboratory (Farmington, Connecticut) and bred to produce
wild-type (mUCP-1+/+) and mUCP-1-null (mUCP-1-/-)
mice. Mice were bred and housed at an ambient temperature
of 30 ˚C to prevent thermal stress to the mUCP-1-/- mice.
All mice were housed in a temperature-controlled environ-
ment maintained at 30 ˚C under a 12:12-h light–dark cycle.
All measurements were conducted at similar times and
dates. All in vivo rat and mice studies were performed at the
Baylor Scott & White Research Institute (BSWRI), Dallas,
TX.
Whole body weights and food intake
Daily weight measurement was performed in the rodents
with an Ohaus-Valor 3000 TREME scale. Animals were
fed on high-fat diets (45% Kcal (24 g %) fat; 35% Kcal
(41 g %) carbohydrate; 20% Kcal (24 g %) protein) (cat #
D12451, Research Diets Inc., New Brunswick, NJ) before
performing UTMD gene delivery. Each animal was kept in
individual cages and received the high-fat diet chow daily
for 1 month before the study. Food intake was measured on
a daily basis.
Subcutaneous abdominal fat thickness
measurement with US image
The thickness of SQ adipose tissue was determined by US
image at baseline, day 10 and day 30 post UTMD. An
anatomical area was carefully defined on the left lateral wall
of the abdomen. This area was clipped and a reading was
obtained with an A-mode device using a S12 transducer
with a resonant frequency of 12MHz (Sonos 5500, Philips
Ultrasound, Bothell, WA). The thickness of the sub-
cutaneous abdominal fat layer was then calculated imme-
diately after ultrasonic investigation.
Thermal imaging measurement
Local temperature at both thighs through an infrared ima-
ging technique [23] was measured at baseline, day 10 and
day 30 post UTMD. All the rats and mice were euthanized
30 days after UTMD. Surface temperature of both thighs
was recorded under anesthetized condition using an infrared
digital thermographic camera (T660sc, emissivity of 0.98,
FLiR Systems) placed 20 cm above the animal. The camera
has a thermal sensitivity of ∼0.1 °C and a spatial resolution
of 640 × 480 pixels [24].
Non-viral site-specific UTMD gene therapy
Animals were anesthetized with intraperitoneal ketamine
(60 mg/kg) and xylazine (5 mg/kg), and a polyethylene tube
(PE 50 for rat, PE 10 for mouse Becton Dickinson, Franklin
Lakes, TN, USA) was inserted into the right internal jugular
vein by surgical cut down. The hyPB transposon donor
plasmids and helper plasmids ratio was 5:1. In all, 1 ml of
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microbubble suspension containing 2 mg plasmids (0.5 ml
diluted with 0.5 ml phosphate-buffered solution (PBS)) for a
rat or 100 µl of microbubble suspension containing 200 µg
plasmids (50 µl diluted with 50 µl PBS) for each mouse
were infused over 5 min via pump (Genie, Kent Scientific,
Torrington, CT). During the infusion, US was directed to
the left thigh using a commercially available US transducer
(S3, Sonos 5500, Philips Ultrasound, Bothell, WA). US was
then applied in ultraharmonic mode (transmit 1.3 MHz/
receive 3.6 MHz) at a mechanical index of 1.4. Four bursts
of US were triggered to every fourth end-systole by elec-
trocardiogram using a delay of 45–70 ms after the peak of
the R wave. These settings have shown to be optimal for
plasmid delivery by UTMD using this instrument [59].
Microbubble destruction was visually apparent in all ani-
mals. After UTMD, the jugular vein was tied off, the skin
closed, and the animals allowed to recover. All animals
were euthanized using an overdose of sodium pentobarbital
(120 mg/kg). SKM tissue was collected from the left (trea-
ted) and right (control) thighs (vastus lateralis) in all ani-
mals. All samples were placed in weigh boats and delivered
to the processing room by the surgical technicians imme-
diately following collection.
Manufacture of plasmid-containing lipid-stabilized
microbubbles
Lipid-stabilized microbubbles were prepared as described
previously [60]. Briefly, a stock solution is prepared con-
taining 270 mg of 1,2-dipalmitoyl-Sn-glycero-3-phospha-
tidylcholine, (Sigma, St. Louis, MO), 30 mg of 1,2-
dipalmitoyl-Sn-glycero-3- phosphatidylethanolamine,
(Sigma, St. Louis, MO), and 1 g of glucose. These ingre-
dients were dissolved in a boiling water bath for 20–30
min, with pipetting of contents up and down until no
visible particles remain. This stock solution was stored at
4–8 ˚C. Plasmid-containing microbubbles were prepared by
mixing 2 mg of dried plasmid with 50 µL of lipofectamine
2000 (Invitrogen, Carlsbad, CA) and incubating at room
temperature for 15 min. This liposome/plasmid DNA
mixture was added to 400 µL of lipid stock solution, 50 µL
of pure glycerol, and 5 µL of 10% albumin solution, mixed
well with a pipette, and then placed in ice. Aliquots of 0.5
mL of this phospholipid–plasmid solution were placed in
1.5 mL clear vials; the air in the headspace of the vials was
replaced with perfluoropropane gas (Air Products, Inc.,
Allentown, PA). Each vial was incubated at 4–8˚C for
30 min and then mechanically shaken for 30 s by a dental
amalgamator (VialmixTM, Bristol-Myers Squibb Medical
Imaging, N. Billerica, MA). The mean diameter and con-
centration of the microbubbles in the upper layer
were measured by a particle counter (Beckman Coulter
Multisizer III).
Plasmid cDNA constructs
PRDM16 cDNA (Cat#: 15503, Addgene Company, Cam-
bridge, MA), PGC-1α cDNA (Cat#: 10974, Addgene),
BMP7 cDNA (Cat#: sc119058, OriGene Technologies),
DsRed cDNA (Clontech Laboratories), were subcloned into
PiggyBac transposon plasmids (pXL-BSII donor plasmid)
provided by Dr. Fraser at the University of Notre Dame
(Notre Dame, IN, USA) [61], and hyperactive piggyBac
transposase helper plasmid was provided by Dr. Bradley at
Wellcome Trust Sanger Institute (Cambridge, UK) [62].
Cloning, isolation, and purification of the plasmids were
performed by standard procedures, and the PCR products
were sequenced to confirm that no artefactual mutations
were present.
Immunohistochemistry
Tissue samples were fixed in 10% formalin for 24 h and
transferred into 70% alcohol for paraffin embedding and 4%
paraformaldehyde and 20% sucrose overnight at 4 °C for
frozen sections. Cryostat sections 5–8 µm in thickness were
further fixed with acetone (–20 °C) for 5 min and quenched
for 5–20 min with 10 mM glycine in PBS. Sections were
then rinsed in PBS three times, and permeabilized with
0.5% Triton X-100 in PBS for 15 min. The primary anti-
bodies (rabbit polyclonal mUCP-1 antibody, rabbit poly-
clonal PRDM16 antibody, mouse recombinant monoclonal
Myf5 antibody (OriGene Technologies, Rockville, MD),
and rabbit polyclonal perilipin A antibody (Abcam Inc.,
Cambridge, MA)), were added and incubated at 4 ˚C
overnight. After washing with PBS three times for 5 min
each time, the secondary antibody was added and incubated
for 1 h at room temperature. DAPI (1:5000 dilutions)
staining for 5 min. Sections were rinsed three times with
PBS for 5 min each time and then mounted. The neutral
lipid dye oil red O (Sigma, St. Louis, MO) was used in
combination with immunofluorescence [25]. Oil red O was
applied to the sections for 5 min (following 5-min washes in
PBS). Slides were then rinsed 30 s in dd H2O followed by a
10-min wash under cold, slow running tap water. Coverslips
were mounted to the dried slides using an anti-fade medium.
All IHC presented in the results were representative of
protein expression for both mice and rat samples.
RNA isolation and quantitative RT-PCR analysis
Total RNA was isolated from 50 mg of SKM using the
RNeasy mini kit (Qiagen). Real-time qRT-PCR analysis
was performed on an ABI 7700 Sequence Detector
(Applied Biosystems, Grand Island, NY, USA) using
SYBR Green (RT2 SYBR Green qPCR Kit; Qiagen, Bos-
ton, MA, USA). Data were normalized to the expression of
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housekeeping genes (as an endogenous control). Changes in
gene expression were normalized to control SKM samples.
Primers were designed and synthesized by IDT Company.
Western blotting
Total protein extracts from skeletal tissue were evaluated
with a Cytoplasmic and Nuclei Extraction Kit (Thermo
Scientific, Rockford, IL, USA). Protein concentrations were
determined using the BCA-200 Protein Assay kit (Pierce,
Grand Island, NY, USA); equal amounts of protein were
separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis to nitrocellulose membranes and incubated
with primary antibodies included anti-PRDM16 (1:1000
dilutions), anti-mUCP-1 (1:2000 dilution), anti-perilipin A
(1:2000 dilution), and anti-actin (1:2000 dilutions). Horse-
radish peroxidase secondary antibodies were used, and
chemiluminescence was determined using the SuperSignal
West Dura detection system (Pierce); Cytoplasmic marker
(actin) was used to confirm equal loading. All western blots
were performed in duplicate.
Data analysis
Data were analyzed using Statview software (SAS, Cary,
NC, USA). The values are presented as mean ± SEM. Dif-
ferences were analyzed by repeated-measures ANOVA with
Fisher’s post hoc test and were considered significant at p <
0.05.
Author contributions All authors listed, have made substantial, direct,
and intellectual contribution to the work, and approved it for pub-
lication. In particular: RAB conceived the rationale to use UTMD in
muscle tissue to express BAT thermogenic genes. SC and RAB
designed the experiment. SC, J-SS, and PH performed the experi-
ments, contributed reagents/materials/analysis tools and designed the
figures. RAB, EJN-G, and JWK wrote the introduction and analyzed
the data; RAB, ER-A, and AL-N wrote the conclusions and performed
literature review. JWK, RADF, and PAG are senior authors that proof-
read the manuscript and substantially contributed to the conclusions
and study design.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
References
1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono
C, et al. Global, regional, and national prevalence of overweight
and obesity in children and adults during 1980-2013: a systematic
analysis for the Global Burden of Disease Study 2013. Lancet
(Lond, Engl). 2014;384:766–81.
2. Aslibekyan S, Garvey WT. Obesity: obesity and cardiometabolic
disease - more than meets the eye. Nat Rev Endocrinol. 2017;13:
566–8.
3. Ochner CN, Barrios DM, Lee CD, Pi-Sunyer FX. Biological
mechanisms that promote weight regain following weight loss in
obese humans. Physiol Behav. 2013;120:106–13.
4. Lagerros YT, Rossner S. Obesity management: what brings suc-
cess? Ther Adv Gastroenterol. 2013;6:77–88.
5. Betz MJ, Enerback S. Targeting thermogenesis in brown fat and
muscle to treat obesity and metabolic disease. Nat Rev Endocri-
nol. 2017;14:77–87.
6. Halpern B, Mancini MC, Halpern A. Brown adipose tissue: what
have we learned since its recent identification in human adults.
Arq Bras Endocrinol Metabol. 2014;58:889–99.
7. Spiegelman BM. Banting Lecture 2012: regulation of adipogen-
esis: toward new therapeutics for metabolic disease. Diabetes.
2013;62:1774–82.
8. Katterle Y, Keipert S, Hof J, Klaus S. Dissociation of obesity and
insulin resistance in transgenic mice with skeletal muscle expres-
sion of uncoupling protein 1. Physiol Genom. 2008;32:352–9.
9. Voigt A, Katterle Y, Kahle M, Kluge R, Schurmann A, Joost HG,
et al. Skeletal muscle mitochondrial uncoupling prevents diabetes
but not obesity in NZO mice, a model for polygenic diabesity.
Genes Nutr. 2015;10:57.
10. Keipert S, Voigt A, Klaus S. Dietary effects on body composition,
glucose metabolism, and longevity are modulated by skeletal
muscle mitochondrial uncoupling in mice. Aging Cell.
2011;10:122–36.
11. O’Neill SM, Hinkle C, Chen SJ, Sandhu A, Hovhannisyan R,
Stephan S, et al. Targeting adipose tissue via systemic gene
therapy. Gene Ther. 2014;21:653–61.
12. Lukashev AN, Zamyatnin AA Jr.. Viral vectors for gene therapy:
current state and clinical perspectives. Biochem (Mosc).
2016;81:700–8.
13. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with
the use of viral vectors for gene therapy. Nat Rev Genet.
2003;4:346–58.
14. Chen ZY, Yang F, Lin Y, Zhang JS, Qiu RX, Jiang L, et al. New
development and application of ultrasound targeted microbubble
destruction in gene therapy and drug delivery. Curr Gene Ther.
2013;13:250–74.
15. Geis NA, Katus HA, Bekeredjian R. Microbubbles as a vehicle for
gene and drug delivery: current clinical implications and future
perspectives. Curr Pharm Des. 2012;18:2166–83.
16. Zhang L, Sun Z, Ren P, Lee RJ, Xiang G, Lv Q, et al. Ultrasound-
targeted microbubble destruction (UTMD) assisted delivery of
shRNA against PHD2 into H9C2 cells. PLoS ONE. 2015;10:
e0134629.
17. Chen S, Shimoda M, Chen J, Matsumoto S, Grayburn PA.
Transient overexpression of cyclin D2/CDK4/GLP1 genes indu-
ces proliferation and differentiation of adult pancreatic progenitors
and mediates islet regeneration. Cell Cycle (Georget, Tex).
2012;11:695–705.
18. Frost PA, Chen S, Mezzles MJ, Voruganti VS, Nava-Gonzalez EJ,
Arriaga-Cazares HE, et al. Successful pharmaceutical-grade
streptozotocin (STZ)-induced hyperglycemia in a conscious teth-
ered baboon (Papio hamadryas) model. J Med Primatol.
2015;44:202–17.
19. Chen S, Bastarrachea RA, Roberts BJ, Voruganti VS, Frost PA,
Nava-Gonzalez EJ, et al. Successful beta cells islet regeneration in
streptozotocin-induced diabetic baboons using ultrasound-targeted
microbubble gene therapy with cyclinD2/CDK4/GLP1. Cell
Cycle (Georget, Tex). 2014;13:1145–51.
20. Vu V, Liu Y, Sen S, Xu A, Sweeney G. Delivery of adiponectin
gene to skeletal muscle using ultrasound targeted microbubbles
improves insulin sensitivity and whole body glucose homeostasis.
Am J Physiol Endocrinol Metab. 2013;304:E168–75.
21. Farmer SR. Brown fat and skeletal muscle: unlikely cousins? Cell.
2008;134:726–7.
S. Chen et al.
22. Bastarrachea RA, Chen J, Kent JW Jr., Nava-Gonzalez EJ,
Rodriguez-Ayala E, Daadi MM, et al. Engineering brown fat into
skeletal muscle using ultrasound-targeted microbubble destruction
gene delivery in obese Zucker rats: proof of concept design.
IUBMB Life. 2017;69:745–55.
23. Crane JD, Mottillo EP, Farncombe TH, Morrison KM, Steinberg GR.
A standardized infrared imaging technique that specifically detects
UCP1-mediated thermogenesis in vivo. Mol Metab. 2014;3:490–4.
24. Jang C, Jalapu S, Thuzar M, Law PW, Jeavons S, Barclay JL,
et al. Infrared thermography in the detection of brown adipose
tissue in humans. Physiol Rep. 2014;2:e12167.
25. Strauss JA, Shaw CS, Bradley H, Wilson OJ, Dorval T, Pilling J,
et al. Immunofluorescence microscopy of SNAP23 in human
skeletal muscle reveals colocalization with plasma membrane,
lipid droplets, and mitochondria. Physiol Rep. 2016;4:e12662.
26. Kimmel AR, Sztalryd C. Perilipin 5, a lipid droplet protein
adapted to mitochondrial energy utilization. Curr Opin Lipidol.
2014;25:110–7.
27. Frontini A, Cinti S. Distribution and development of brown adi-
pocytes in the murine and human adipose organ. Cell Metab.
2010;11:253–6.
28. Cinti S. Between brown and white: novel aspects of adipocyte
differentiation. Ann Med. 2011;43:104–15.
29. Cui XB, Chen SY. White adipose tissue browning and obesity. J
Biomed Res. 2016;31:1–2.
30. Christian M, Parker MG. The engineering of brown fat. J Mol Cell
Biol. 2010 Feb;2:23–5.
31. Nicholls DG. The physiological regulation of uncoupling proteins.
Biochim Biophys Acta. 2006;1757:459–66.
32. Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE,
et al. White fat progenitor cells reside in the adipose vasculature.
Science. 2008;322:583–6.
33. Atit R, Sgaier SK, Mohamed OA, Taketo MM, Dufort D, Joyner
AL, et al. Beta-catenin activation is necessary and sufficient to spe-
cify the dorsal dermal fate in the mouse. Dev Biol. 2006;296:164–76.
34. Timmons JA, Wennmalm K, Larsson O, Walden TB, Lassmann
T, Petrovic N, et al. Myogenic gene expression signature estab-
lishes that brown and white adipocytes originate from distinct cell
lineages. Proc Natl Acad Sci USA. 2007;104:4401–6.
35. Mezentseva NV, Kumaratilake JS, Newman SA. The brown
adipocyte differentiation pathway in birds: an evolutionary road
not taken. BMC Biol. 2008;6:17.
36. Rodriguez A, Becerril S, Ezquerro S, Mendez-Gimenez L, Fruh-
beck G. Crosstalk between adipokines and myokines in fat
browning. Acta Physiol (Oxf). 2017;219:362–81.
37. Li F, Li Y, Duan Y, Hu CA, Tang Y, Yin Y. Myokines and
adipokines: involvement in the crosstalk between skeletal muscle
and adipose tissue. Cytokine Growth Factor Rev. 2017;33:73–82.
38. Bach AD, Arkudas A, Tjiawi J, Polykandriotis E, Kneser U,
Horch RE, et al. A new approach to tissue engineering of vas-
cularized skeletal muscle. J Cell Mol Med. 2006;10:716–26.
39. Keipert S, Ost M, Johann K, Imber F, Jastroch M, van Schothorst
EM, et al. Skeletal muscle mitochondrial uncoupling drives
endocrine cross-talk through the induction of FGF21 as a myo-
kine. Am J Physiol Endocrinol Metab. 2014;306:E469–82.
40. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F,
et al. FGF21 regulates PGC-1alpha and browning of white adipose
tissues in adaptive thermogenesis. Genes Dev. 2012;26:271–81.
41. Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA.
Immunohistochemistry as an important tool in biomarkers detec-
tion and clinical practice. Biomark Insights. 2010;5:9–20.
42. Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E,
Hamilton-Dutoit S. Real-time quantitative PCR of microdissected
paraffin-embedded breast carcinoma: an alternative method for
HER-2/neu analysis. J Mol Diagn. 2004;6:42–51.
43. Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y.
Real-time PCR complements immunohistochemistry in the
determination of HER-2/neu status in breast cancer. BMC Clin
Pathol. 2006;6:2.
44. Sawada T, Miyoshi H, Shimada K, Suzuki A, Okamatsu-Ogura Y,
Perfield JW, et al. Perilipin overexpression in white adipose tissue
induces a brown fat-like phenotype. PLoS ONE. 2010;5:e14006.
45. Tseng YH, Kokkotou E, Schulz TJ, Huang TL, Winnay JN,
Taniguchi CM, et al. New role of bone morphogenetic protein 7 in
brown adipogenesis and energy expenditure. Nature. 2008;454:
1000–4.
46. Kajimura S, Seale P, Kubota K, Lunsford E, Frangioni JV, Gygi
SP, et al. Initiation of myoblast to brown fat switch by a
PRDM16-C/EBP-beta transcriptional complex. Nature.
2009;460:1154–8.
47. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control
of mitochondrial biogenesis: the central role of PGC-1alpha.
Cardiovasc Res. 2008;79:208–17.
48. Seale P. Transcriptional regulatory circuits controlling brown fat
development and activation. Diabetes. 2015;64:2369–75.
49. Seale P, Kajimura S, Yang W, Chin S, Rohas LM, Uldry M, et al.
Transcriptional control of brown fat determination by PRDM16.
Cell Metab. 2007;6:38–54.
50. Hill JO, Peters JC, Wyatt HR. Using the energy gap to address
obesity: a commentary. J Am Diet Assoc. 2009;109:
1848–53.
51. Melby CL, Paris HL, Foright RM, Peth J. Attenuating the biologic
drive for weight regain following weight loss: must what goes
down always go back up? Nutrients. 2017;9:468.
52. Schutz Y, Byrne NM, Dulloo A, Hills AP. Energy gap in the
aetiology of body weight gain and obesity: a challenging concept
with a complex evaluation and pitfalls. Obes Facts. 2014;7:
15–25.
53. Dulloo AG. Explaining the failures of obesity therapy: willpower
attenuation, target miscalculation or metabolic compensation? Int
J Obes. 2012;36:1418–20. 2005
54. Dulloo AG. Translational issues in targeting brown adipose tissue
thermogenesis for human obesity management. Ann N Y Acad
Sci. 2013;1302:1–10.
55. Major GC, Doucet E, Trayhurn P, Astrup A, Tremblay A. Clinical
significance of adaptive thermogenesis. Int J Obes. 2007;31:
204–12. 2005
56. Marlatt KL, Ravussin E. Brown adipose tissue: an update on
recent findings. Curr Obes Rep. 2017;6:389–96.
57. Park A, Kim WK, Bae KH. Distinction of white, beige and brown
adipocytes derived from mesenchymal stem cells. World J Stem
Cells. 2014;6:33–42.
58. Wood WM, Etemad S, Yamamoto M, Goldhamer DJ. MyoD-
expressing progenitors are essential for skeletal myogenesis and
satellite cell development. Dev Biol. 2013;384:114–27.
59. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo
reprogramming of adult pancreatic exocrine cells to beta-cells.
Nature. 2008;455:627–32.
60. Chen S, Shohet RV, Bekeredjian R, Frenkel P, Grayburn PA.
Optimization of ultrasound parameters for cardiac gene delivery of
adenoviral or plasmid deoxyribonucleic acid by ultrasound-
targeted microbubble destruction. J Am Coll Cardiol. 2003;42:
301–8.
61. Cary LC, Goebel M, Corsaro BG, Wang HG, Rosen E, Fraser MJ.
Transposon mutagenesis of baculoviruses: analysis of Trichoplu-
sia ni transposon IFP2 insertions within the FP-locus of nuclear
polyhedrosis viruses. Virology. 1989;172:156–69.
62. Yusa K, Zhou L, Li MA, Bradley A, Craig NL. A hyperactive
piggyBac transposase for mammalian applications. Proc Natl
Acad Sci USA. 2011;108:1531–6.
Ectopic BAT mUCP-1 overexpression in SKM by delivering a BMP7/PRDM16/PGC-1a gene cocktail or single. . .
View publication stats
